TB AND HIV/AIDS THE SITUATION AT BMC Care & Treatment Unit CME, 5/5/20166 PRESENTERS: Dr. Desideris Bernard, Dr. Magawa.

Slides:



Advertisements
Similar presentations
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Advertisements

June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.
World Health Organization TB Case Definitions
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
Accelerating PMDT scale up in Ethiopia
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
KEY CHANGES IN THE NEW NTBLCP GUIDELINES
In the name of God Fariba Rezaeetalab Assistant Professor.
Annabel Baddeley Global TB Programme WHO, Geneva
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
COUNTRY XEPERIENCE AND RESPONSE TO MDR AND XDR TUBERCULOSIS PRESENTED AT THE WHO TB/HIV PLANNING MEETING, ADDIS ABBABA, 11-12, NOVEMBER 2008 BY MS GUGU.
Diagnosis of TB.
Unit 5: IPT Isoniazid TB Preventive Therapy
experience from Lesotho
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
Challenge 4: Linking TB & HIV/AIDS Programs Kayt Erdahl, Project HOPE Rodrick Nalikungwi, Project HOPE Malawi December 18, 2008.
A cost-effectiveness evaluation of preventive interventions for HIV-TB in Sub-Saharan Africa (Tanzania): Relevance for neurological infections Lucie Jean-Gilles.
Paediatric Tuberculosis in HIV Era
“Don’t tell me TB is under control!” Understanding TB
TUBERCULOSIS * Prevention * Treatment, and * Challenges.
T UBERCULOSIS. P HYSICAL ILLNESS Physical illness among IDUs is more common as compared to the general population A Study from Chennai conducted in 2005.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
IMPLEMENTATION PLAN TO SCALE UP HIV/AIDS PREVENTION AND TREATMENT 1.
Challenges of service integration: the TB model Linda-Gail Bekker The Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, South.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Welcome to I-TECH Nurse Clinical Seminar Series 19 August WHO Recommendations for TB Screening and IPT among People Living with HIV Stacie C.
Experience with Tb diagnostics and Scale up of services Botswana, Nigeria, and Tanzania Ernest Ekong, MD,MPH National Clinical Coordinator Harvard PEPFAR.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
Adult Medical-Surgical Nursing Respiratory Module: Tuberculosis.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Dr. Hind E. Satti Partners In Health, Lesotho March, 2008.
Coordinator: Kézdi- Zaharia E. Iringó First author: Magyar Júlia Coauthor: Gyerő Réka.
Ukrainian TB mortality assessment 2008: Low HIV awareness and access to ART for TB patients associated with high HIV related TB mortality Presenting author:
TB/HIV management survey  Baseline audit in parallel with guidelines development process  Survey of clinician opinion and practice  Data collection.
World Bank Seminar Series: Global Issues Facing Humanity Diseases without borders.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
HIV/TB Integration in a Network of Voluntary Counseling/Testing Centers in HAITI Reynold Grand’Pierre MD, Marie Suze Jacquet MD, Jean W. Pape MD PEPFAR.
Infection Control in Tanzania Dr. Peter C. Mgosha (MPH,) MINISTRY OF HEALTH AND SOCIAL WELFARE NATIONAL AIDS COTROL PROGRAMME P.O.BOX DAR Es SALAAM.
Q1 Which of the following descriptions about HIV and TB interaction is right ? Which of the following descriptions about HIV and TB interaction is right.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Intensified TB case finding and infection control in Tanzania – opportunities and challenges Denis Tindyebwa Technical Director EGPAF Tanzania.
Tuberculosis By Fion Kung. Objective  Describe tuberculosis  Describe sigh and symptoms of tuberculosis  Describe the nursing diagnosis for tuberculosis.
TB and HIV integrated services at Martin Preuss Centre in Lilongwe, Malawi : “The Lighthouse Trust initiative” Dr Sam Phiri Executive Director Lighthouse.
TB-H V Co-infection by Dr. Ker Hong Bee 11. LEARNING OBJECTIVES To know & understand about TB-HIV co- infection in relation to:- – interaction & prevalence.
Roundtable. Detection and treatment of TB Andrew Black.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
EPIDEMIOLOGY OF PULMONARY TUBERCULOSIS. LEARNIN G OBJECTIVES State the diagnostic criteria of pulmonary tuberculosis Describe trend & state reasons for.
Sarah Al-Obaydi M.B.Ch.B, MPH(c) Fulbright scholar.
Treatment Action Group TB/HIV Advocacy Toolkit August 2017
TB AND HIV/AIDS THE SITUATION AT BMC
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
This is an archived document.
Treatment Action Group TB/HIV Advocacy Toolkit NOVEMBER 2017
Dr Dawood Quiz questions.
Epidemiology of pulmonary tuberculosis
World Health Organization
Enablers for nationwide expansion of collaborative TB/HIV activities
Screening and diagnosing TB in PLHIV: Challenges and ways forward
Indian Scenario HIV Situation TB Situation
Surveillance for TB in HIV Care and Treatment Settings (CTS)
DSD and TB/HIV services in Zimbabwe
Presentation transcript:

TB AND HIV/AIDS THE SITUATION AT BMC Care & Treatment Unit CME, 5/5/20166 PRESENTERS: Dr. Desideris Bernard, Dr. Magawa

INTRODUCTION

TB/HIV Global situation TB and HIV have been declared as global emergencies demanding global attention(NACP,2015) Worldwide, 34.3 million people are living with HIV. Of these, 24.5 million (71%) live in sub-Saharan Africa and approximately one third are co-infected with TB Globally in 2014, there were an estimated 9.6 million incident cases of TB: 5.4 million among men, 3.2 million among women and 1.0 million among children. Of those who suffer TBs-related mortality, 31% are HIV-infected Some countries have documented up to 70% of TB patients are HIV positive.

.

.

Tanzania and the burden of TB/HIV In Tanzania, TB cases have increased six-fold from 11,843 in 1983 to 64,267 in 2009, mainly due to HIV/AIDS. About 37% of TB patients in Tanzania are co-infected with HIV, accounting for 60-70% of the increase in the number of TB patients. About 41.5% of new TB patients present with smear positive pulmonary tuberculosis (PTB+) and 36.2% with smear negative pulmonary tuberculosis (PTB-) and 22.3% presented with ETB in 2009

INTERACTION OF TB & HIV HIV -↑number of TB cases and alters the clinical course of TB disease. As HIV infection progresses → CD4+ T- lymphocytes decline in number and function. Thus, the immune system becomes less able to prevent the growth and local spread of M. tuberculosis The most common types of TB in HIV are disseminated and extra pulmonary TB

TB/HIV IN THE MEDICAL WARDS In the US, HIV clients accounts for 22% of re- admission (59% higher than non-HIV cases) but TB/HIV is <1% in the medical wards. TB/HIV co-infection lead to prolonged hospital stay and significantly affect the economic status of clients (especially MDR TB –av USD per person globaly). A study at MNH medical wards, TB/HIV was reported the major cause of morbidity (27.9%) and mortality (39.6%) [Desderius BM, Munseri P, Pallangyo KJ 2015]

EFFORTS TO REDUCE BURDEN OF TB ART initiation -Once the diagnosis of TB is made in PLHIV, Start TB Rx within 2 weeks(WHO, 2014) Three I’s o Intensive case finding o Infection control o IPT

Three I’s Intensive case finding – Based on TB screening tool To increase the yield of confirmed cases from TB suspects/presumptive TB cases Infection control – Each POC should take precautions to protect HCWs from acquiring TB and establish IC plans at each POC.

IPT

IPT PROVISION AT BMC IPT Started July 2011 Total clients given IPT - 3,428 (Clients on care – 14,732, Not on ART -5,355)

TB/HIV Co-treatment challenges Concurrent treatment of tuberculosis and HIV is complicated by:- o the adherence challenges of polypharmacy o overlapping side effect profiles of anti-TB and antiretroviral drugs, o immune reconstitution inflammatory syndrome (IRIS), and o drug-drug interactions

HIV/TB SITUATION AT BMC

 At BMC,We are focused and working hard to fight TB through several activities:  EDUCATION Clients:health talk,posters,??Audiovisual TBtrasmission:Airborne,m.tuberculos Risk factors:Time,burden,sunlight,ventilation Staff:TBIC

 SCREENING OF ACTIVE TB TB screen tool:(a) cough of any duration (b) fever of any duration (c) excessive night sweats (d) loss of weight >3kg/1mo Sites:CTC Clinic,VCT,PMTCT,OPDs,Wards,EMD Cough registers

 ISONIAZID PREVENTIVE THERAPY(IPT) Tab 300mg OD of INH for 6months. Repeat after every 2years Eligibility: (a) no current/past h/o hepatitis (b)no h/o of TB Treatment in the past 2 years (c) no non-adherence to long term treatment

(d) no alcohol abuse (e)any medical contraindication to INH (f) no symptoms of peripheral neuropathy  TB INFECTION CONTROL (A)Admistrative measures: TBIC plan: well-ventilated waiting area,consultation room Ensure turn around time of sputum smear,G- Expert in 24hours orientation of all staff on TBIC measures

(B)Environmental measures Open windows and doors Fans Collect sputum outside and away from other people Isolation of TB suspects Isolation of TB patients in the ward

(C)Pesornal Protection Provide handkerchiefs/tissues for all coughing patients Use of mask N95 Reduce time of staying with TB presumptive or active TB Cases

 DIAGNOSIS Smear Microscopy GeneXpert Solid Culture

Test statistics (2015): Tb laboratory register Total smears: 2100 Smear positivity 6.1% Follow up positivity 1% Low grade AFB: 1%

Test statistics(2015): Tb Culture register Smear pos/Culture pos: 55 ( 37%) Smear neg/Culture pos 5 (3.3%) Smear neg/Culture neg: 43 (29%) Smear pos/Culture neg:37 (25%)

Test statistics(2015): GeneXpert Total GeneXpert1252 MTB Not detected (N)1073 MTB detected /Rif neg(T)70 MTB detected / Rif detected ( RR)4 MTB detected/ Rif Indeterminate (I)7 Error23 Invalid63 No result5

Results feedback and reports Results of AFB Smears and GeneXpert released to requesting clinician within 24 hours. Critical results have been identified and are immediately communicated to clinician. If RR in addition to clinician RTLC is informed Customer satisfaction survey of January 2016 does not show negative statements or complaints for AFB smears or GeneXpert

 TREATMENT For new TB/HIV Patients, start ART within two weeks of antTBRX All TB Patient should start ART regardless of CD4 count Initiate co-trimoxazole prophylaxis to all PTB patients regardless of CD4 count Drug-drug interaction:Nevirapine and atazanavir

Regimes  New adult 2RHZE/4RH  All retreatment and defaulters 2RHZE/1RHZE/5RHZE  Rifampicin resistant MDRTB RX

DOT -Treatment supporter -DOT Nurse or HCW

Trends of TB at BMC, TB AMONG NON-HIV

BMC Trends of TB/HIV co-Infection

Trends of Types of TB/HIV co-infection 2015

Annual Trends for types TB in HIV 2015/2016

WAY FOWARD

THE FUTURE OF BMC ON TB Dx & Rx Capacity building for TB culture o Microscopy -AFB o Gene expert/RIF o ?Line probe assay o ?DST o ?LAM test o ?ADA test Establishment of MDR centre - MOH has appointed BMC as one of MDRTB Initiation site (once negative pressure is established)

WABEJA!